Conference Coverage
Latest Content
Aug 03, 2026 | Commentary
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
LGBTQ+ Medical Students Favor States With Protections
Aug 03, 2026
Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD
Aug 03, 2026
Pediatric Chronic Skin Disorders Linked to Poorer Mental Health
Aug 03, 2026
The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD
Aug 03, 2026
Advertisement
Shorts
0:38
Why Rheumatologists Are Key to Lung Health: Steven Nathan, MD
3 days ago
by
Sabrina McCrear(+1 more)
0:47
What PCSK9 Inhibitors Reveal About Innovation, Access: Deepak Bhatt, MD, MPH, MBA
4 days ago
by
Pearl Steinzor(+1 more)
0:42
How Fraudulent Claims Are Inflating ACO Costs: Aisha Pittman, MPH
4 days ago
by
Pearl Steinzor(+1 more)
2:06
Expanding the GLP-1 Pipeline for Diabetes Care: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
5 days ago
by
Pearl Steinzor(+1 more)
0:42
The "Rule of 7" for Remdesivir Treatment: Nitipong Permpalung, MD, MPH
5 days ago
by
Sabrina McCrear(+1 more)
0:58
The Surprising Reality of C. Diff in Your Home: Bruce Hirsch, MD
5 days ago
by
Sabrina McCrear(+1 more)
1:00
Exploring Tirzepatide’s Potential Cardiovascular Benefits: Deepak Bhatt, MD, MPH, MBA
6 days ago
by
Pearl Steinzor(+1 more)
0:55
CD19, a Smart Target With a Trade-Off: Martin Schrappe, MD, PhD
9 days ago
by
Maggie L. Shaw(+1 more)
0:32
How SkinIO's Full Body Scan Caught Melanoma: Steve Bonner
11 days ago
by
Giuliana Grossi
0:29
The Importance of Context When Using Polygenic Risk Scores: David Zhang, MD
11 days ago
by
Sabrina McCrear(+1 more)
Personalized Expert Insights
Have a question about bispecific therapy? Connect with experts who have the answers.
A Conference You Don't Want To Miss
Two days of strategy, insights, and innovation in patient-centered oncology care. September 24–25.
Center on Health Equity & Access
Start seeing what truly shapes access and learn how you can redefine the landscape.
Free Webinar: A Look at PBM Reform and Transparency
Experts from oncology practice, policy law and PBM operations share their perspectives.
Stay Ahead of Clinical and Policy Change
AJMC's e-newsletter features payer-focused insights across priority disease areas.
Center on Health Equity & Access
Advertisement
All News
Advertisement
Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.
Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.
The new MonumenTAL-6 combination data appear to exceed MajesTEC-9 numbers.
FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.
The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.
People with HIV born after 1980 had an 81% lower risk of hepatitis B coinfection than earlier cohorts, highlighting the lasting impact of childhood vaccination.
Black, Latino boys' stigma persists; AHRQ halts 100+ grants; Delgocitinib succeeds in teens; Medicaid frail rule stands; BIPOC eating care improves.
New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.
Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.
An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5